Ad hoc: Epigenomics AG: Ad hoc Announcement According to §15 WpHG (German Securities Trading Act): Epigenomics AG and Philips Collaborate on Integrated Automation Solutions for DNA Methylation-based C

Epigenomics AG / Miscellaneous cooperation, License / Ad hoc: Ad hoc
Announcement According to §15 WpHG (German Securities Trading
Act): Epigenomics AG and Philips Collaborate on Integrated Automation
Solutions for DNA Methylation-based Cancer Diagnostics

Ad hoc announcement according to §15 WpHG processed and transmitted
by Hugin. The issuer is solely responsible for the content of this
announcement.

----------------------------------------------------------------------
--------------

Berlin, December 19, 2008 - Epigenomics AG (Frankfurt Prime Standard:
ECX; ISIN: DE000A0BVT96) and Royal Philips Electronics (NYSE: PHG,
AEX: PHI) today entered into a collaboration and licensing agreement
focusing on novel technologies and methods targeted at the diagnosis
of various cancers.
Under the agreement both parties will jointly perform feasibility
studies aimed at developing an integrated and fully automated
instrument platform for the diagnosis of certain cancers based on DNA
methylation biomarkers. In addition, Philips obtained the option to
license the required technologies and biomarkers separately or in
combination for diagnostic applications. The option may be exercised
upon the successful completion of the feasibility studies. Financial
details are not disclosed.

End of ad hoc

Contact:

Epigenomics AG
Dr. Achim Plum
Sen. VP Corporate Development
Kleine Praesidentenstr. 1
10178 Berlin
Germany
+49 30 24345 368 (phone)
+49 30 24345 555 (fax)
achim.plum@epigenomics.com
www.epigenomics.com

Disclaimer

This communication expressly or implicitly contains certain
forward-looking statements concerning Epigenomics AG and its
business. Such statements involve certain known and unknown risks,
uncertainties and other factors which could cause the actual results,
financial condition, performance or achievements of Epigenomics AG to
be materially different from any future results, performance or
achievements expressed or implied by such forward-looking statements.
Epigenomics AG is providing this communication as of this date and
does not undertake to update any forward-looking statements contained
herein as a result of new information, future events or otherwise.

--- End of Message ---

Epigenomics AG
Kleine Präsidentenstr.1 Berlin Germany

WKN: A0BVT9;
ISIN: DE000A0BVT96; Index: CDAX, Prime All Share, TECH All Share;
Listed: Amtlicher Markt in Frankfurter Wertpapierbörse, Prime
Standard in Frankfurter Wertpapierbörse,
Freiverkehr in Börse Berlin, Freiverkehr in Börse Düsseldorf,
Freiverkehr in Hanseatische Wertpapierbörse zu Hamburg, Freiverkehr
in Bayerische Börse München,
Freiverkehr in Börse Stuttgart;
Copyright © Hugin AS 2008. All rights reserved.